Power3 Medical Products, Inc., a development stage company, engages in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, amyotrophic lateral sclerosis (ALS), Alzheimer?s disease, and Parkinson?s disease. Its product candidates include BC-SeraPro, a blood serum protein breast cancer test for the diagnosis of breast cancer and to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The company’s products also comprise NuroPro, a blood serum protein neurodegenerative disease diagnostic screening test for disease diagnostics, such as neurological diseases of motor control, such as Parkinson?s disease, ALS, and similarly disorders; ALS specific tests for ALS vs. ALS-like disorders; Alzheimer?s disease specific tests; and a Parkinson?s disease specific test.
Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid tests used primarily to diagnose human diseases and screen donated human blood in North America and internationally. The company markets a portfolio of products to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, and other infections. Its primarily product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas;
GPRO is currently up in the market $0.70(1.62%) which is pretty close to their highest mark-up for the day at $43.85 a share. Their last trade was setg at $43.80 a share and they have gone over their average volume count by 7k.
Sign up for free stock alerts at http://www.pennygovernance.com/
***************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
